Plain-English translation of NCT07318259 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing ultra-fast autologous BCMA/CD70-targeted CAR-T therapy, a personalized cell treatment for people with lupus that hasn't responded to conventional drugs. Researchers take your own immune cells, reprogram them in the laboratory to recognize and destroy the cells causing lupus, and then return them to your body. This approach is different from existing treatments because it aims to eliminate the root cause of the disease rather than just manage symptoms.
Current lupus treatments like steroids and immunosuppressants can control symptoms but don't cure the disease, leaving patients dependent on lifelong medication and at risk of flare-ups when drugs are stopped. This trial exists to test whether this new treatment can offer a more lasting solution for people whose lupus has not responded adequately to at least two or three standard therapies.
You likely qualify if…
You likely don't qualify if…
You will have blood collected through a procedure called leukapheresis so doctors can harvest your immune cells. These cells will be reprogrammed in the laboratory over about 10 minutes, then returned to your body as an infusion. The trial is designed to gradually test increasing doses of the treatment in a small group of 18 participants. You will be closely monitored afterward to evaluate whether the treatment is safe and effective, with follow-up visits and blood tests to track your lupus activity and any side effects.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Chongqing Precision Biotech Co., Ltd
Enrollment target
~18 participants
Started
January 2026
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lingyun Sun
Chongqing Precision Biotech Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.